Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Free Report) was the target of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totalling 270,300 shares, a decrease of 71.7% from the June 15th total of 955,200 shares. Based on an average daily volume of 629,200 shares, […]
Short Interest in Talaris Therapeutics, Inc (NASDAQ:TALS) Decreases By 71 7% theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Talaris Therapeutics (NASDAQ:TALS – Get Rating) and Cardiol Therapeutics (NASDAQ:CRDL – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends. Risk & Volatility Talaris Therapeutics has a beta of […]
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 16,870 shares of the company’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $2.59, for a total value of $43,693.30. Following the transaction, the director now directly owns 3,798,542 shares of the company’s stock, valued […]
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 12,942 shares of Talaris Therapeutics stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $2.49, for a total value of $32,225.58. Following the completion of the transaction, the director now directly owns 3,771,392 shares in the […]